Brain Chemistry Labs

Brain Chemistry Labs is a biotechnology startup with a mission to discover new treatments for brain diseases by studying proven patterns of wellness and disease. Their research has revealed that chronic exposure to BMAA can trigger Alzheimer’s-like brain tangles and amyloid deposits, marking a groundbreaking discovery in the field. Founded in 2007, the company has made significant strides in identifying two promising new drugs for ALS, Alzheimer’s, Parkinson’s, and other tangle diseases, with a third drug in development. The innovative approach of Brain Chemistry Labs, rooted in the study of indigenous people's health, presents a unique and promising pathway to finding cures for serious illnesses. Their work has garnered attention in the industries of Biotechnology, Health Care, Manufacturing, and Pharmaceutical. While specific details about the headquarter location and past investment history are currently unavailable, the potential demonstrated by Brain Chemistry Labs in approaching brain disease treatment from a fresh perspective positions them as a compelling opportunity for venture capital investors interested in the healthcare and biotechnology sectors.